An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis

Curr Oncol. 2022 Jun 17;29(6):4342-4353. doi: 10.3390/curroncol29060347.


Introduction: With the increasing use of immune checkpoint inhibitors (ICI) for cancer, there is a growing burden on the healthcare system to provide care for the toxicities associated with these agents. Herein, we aim to identify and describe the distribution of encounters seen in an urgent care setting for immune-related adverse events (irAEs) and the clinical outcomes from irAE management.

Methods: Patient demographics, disease characteristics, and treatment data were collected retrospectively from encounters at an oncology Urgent Care Clinic (UCC) from a single tertiary center for upper aerodigestive malignancies from 1 July 2018 to 30 June 2019. Data were summarized using descriptive statistics with odds ratios for associations between patient features and hospitalization after UCC evaluation.

Results: We identified 494 encounters from 289 individual patients over the study period. A history of ICI therapy was noted in 34% (n = 170/494) of encounters and 29 encounters (29/170, 17%) were confirmed and treated as irAEs. For those treated for irAEs, the majority (n = 19/29; 66%) were discharged home. Having an irAE was associated with an increased risk of hospitalization compared to non-irAEs (OR 5.66; 95% CI 2.15-14.89; p < 0.001).

Conclusion: In this single institution experience, the majority of UCC encounters for confirmed irAEs were safely managed within the UCC. In ICI-treated patients, having an irAE was associated with an increased risk of hospitalization versus non-irAEs.

Keywords: care delivery; immune-checkpoint inhibitors; immune-related adverse events; toxicity; urgent care.

MeSH terms

  • Ambulatory Care Facilities
  • Antineoplastic Agents, Immunological* / therapeutic use
  • Drug-Related Side Effects and Adverse Reactions* / drug therapy
  • Humans
  • Medical Oncology
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Retrospective Studies


  • Antineoplastic Agents, Immunological

Grant support

This research received no external funding.